**Supplementary Table 2:** Quality of life decrements included in the model

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Parameter | Base case  value | Probabilistic  Distribution | One-way sensitivity Range | Source |
|  |  |  |  |  |
| Local spread prostate cancer | 0.16 | Beta | 0.13-0.19 | ([17](#_ENREF_17)) |
| Metastatic spread prostate cancer | 0.33 | Beta | 0.26-0.40 | ([17](#_ENREF_17)) |
| Radiation treatment for prostate cancer | 0.27 | Beta | 0.22-0.32 | ([17](#_ENREF_17)) |
| Hormone treatment for prostate cancer | 0.17 | Beta | 0.14-0.20 | ([17](#_ENREF_17)) |
| Bowel problems from treatment  (proportion who experience it after radiation treatment) (proportion who experience it after hormone treatment) | 0.29   (0.08)  (0.00) | Beta  (beta)  (n/a) | 0.23-0.35  (0.04-0.29)  (n/a) | (26-29)   Expert Opinion ([17](#_ENREF_17)) |
| Impotence from treatment  (proportion who experience it after radiation treatment) (proportion who experience it after hormone treatment) | 0.11  (0.67)  (1.00) | Beta  (beta)  (n/a) | 0.09-0.13  (0.64-0.90)  (n/a) | (26-29)   Expert Opinion ([17](#_ENREF_17)) |
| Incontinence from treatment  (proportion who experience it after radiation treatment) (proportion who experience it after hormone treatment) | 0.17  (0.13)  (0.00) | Beta  (beta)  (n/a) | 0.14-0.20  (0.04-0.33)  (n/a) | (26-29)   Expert Opinion ([17](#_ENREF_17)) |
| Terminal prostate cancer | 0.75 | Beta | 0.60-0.90 | ([17](#_ENREF_17)) |
| Terminal – all cause mortality  (ages 65-84) | 0.54 | Beta | 0.42-0.65 | ([35-39](#_ENREF_35)) |
| Terminal – all cause mortality  (ages 85+) | 0.65 | Beta | 0.57-0.70 | ([35-39](#_ENREF_35)) |
| Death | 1 | n/a | n/a | Expert Opinion |